Germ cell tumours (GCTs) are a diverse group of neoplasms that can be histologically subclassified as either seminomatous or non-seminomatous. These two subtypes have distinct levels of differentiation and clinical characteristics, the non-seminomatous tumours being associated with poorer prognosis. In this article, we review how different patterns of aberrant DNA methylation relate to these subtypes. Aberrant DNA methylation is a hallmark of all human cancers, but particular subsets of cancers show unusually high frequencies of promoter region hypermethylation. Such a 'methylator phenotype' has been described in non-seminomatous tumours. We discuss the possible cause of distinct methylation profiles in GCTs and the potential of DNA methylation to provide new targets for therapy. We also consider how recent developments in our understanding of this epigenetic modification and the development of genome-wide technologies are shedding new light on the role of DNA methylation in cancer aetiology.
Introduction
The methylation of CpG dinucleotides is the most widely studied epigenetic modification and has known roles in normal development and disease pathology. It is primarily believed to participate in the establishment of a stable repressive transcriptional state in conjunction with histone modifications (Portela & Esteller 2010 ). DNA methylation is frequently disrupted in cancer: typically cancer cells display hypomethylation across the genome, attributed to the loss of methylation at repetitive elements, whereas methylation at gene promoter regions is increased. Particularly, tumour suppressor genes are commonly silenced by hypermethylation of their promoter regions as an alternative to loss-of-function mutations (Esteller 2007 , Dawson & Kouzarides 2012 . In some cancer types, particular subpopulations of tumours exhibit an unusually high frequency of gene promoter hypermethylation that can be associated with specific genetic or clinical features (Toyota et al. 1999 , Noushmehr et al. 2010 . This implies that, in some cases, DNA methylation may play a key role in cancer biology.
Studying DNA methylation is especially significant in germ cell tumours (GCTs). These neoplasms are believed to develop from primordial germ cells (PGCs), a cell type that undergoes dynamic changes in DNA methylation, which are not observed in somatic tissues (Looijenga 2009 , Hajkova 2011 . Analysis of DNA methylation in GCTs shows that various subtypes exhibit specific patterns of DNA methylation that can be associated with their degree of differentiation, the types of tissues that they contain and their clinical characteristics (such as sensitivity to therapy) (Lind et al. 2007 ). The underlying cause behind the distinct methylation profiles of GCTs is not fully established. In addition, a lack of studies accurately describing these differential methylation events on a genome-wide scale and associating them with changes in gene expression makes it difficult to establish their consequence. While these tumours are highly treatable, conventional therapies are associated with long-term morbidity especially in paediatric patients (Murray & Nicholson 2010) . Better understanding of the role of DNA methylation in the aetiology of these tumours might, therefore, provide new, more biologically relevant potential targets for a better therapeutic outcome (Okamoto 2012) .
Our understanding of the consequences of CpG methylation is still evolving. Here, we briefly review efforts to identify which genomic locations are differentially methylated in GCTs and which of these events are associated with changes in gene expression and cell phenotype. We emphasise the need to use unbiased genome-wide methods to analyse differential methylation and to investigate the link between changes in DNA methylation and gene expression, which is often overlooked (Esteller 2011). anatomical sites. In adults, GCTs are primarily gonadal (testicular or ovarian) with the majority of cases affecting males. Testicular GCTs represent the most common malignancy in young men. GCTs can also occur at other sites along the midline, particularly in paediatric cases. Such extragonadal GCTs occur predominantly in the mediastinal (chest cavity), retroperitoneal or sacrococcygeal regions and in the ventral midline of the brain (Oosterhuis & Looijenga 2005 , Looijenga 2009 , Murray & Nicholson 2010 .
GCTs are divided into two histologically distinct subtypes: seminomatous and non-seminomatous. Seminomatous tumours typically display similar characteristics to PGCs, including their morphology (Gondos 1993) , gene expression (positive for POU5F1, NANOG, and SOX17 expression but not for SOX2) (Looijenga 2009 ) and loss of imprinting patterns (Bussey et al. 2001 , Kawakami et al. 2006 . Seminomatous GCTs are referred to as seminomas if they occur in the testes or as germinomas in other anatomical locations. Among the non-seminomatous tumours, there are several distinct morphological subtypes, which include embryonal carcinomas (EC), yolk sac tumours (YST), choriocarcinomas (CC), and teratomas ( Fig. 1) . Other than benign teratomas, the non-seminomatous tumours are clinically less favourable and appear to be more differentiated than seminomatous tumours. About half of GCTs found in adults are seminomatous while non-seminomatous tumours represent 30%, the remaining 20% exhibiting mixed seminomatous and non-seminomatous components (although mixed GCTs with seminomatous component are referred to as non-seminomas) (Oosterhuis & Looijenga 2005 , Looijenga 2009 , Tan & Scotting 2013 ).
Children's GCTs are rare compared with adult cases and differ from adult cases in several respects. Fifty per cent of GCTs in children are extragonadal and teratomas represent half of paediatric cases, although these differ considerably from the teratomatous components arising as part of post-pubertal non-seminomatous testicular tumours. Specifically, pre-pubertal teratomas occur as a pure histology, the majority displaying a diploid karyotype, no cytogenetic abnormalities and an organised tissue arrangement and they all are essentially benign (Ulbright 2005 , Frazier et al. 2012 . Post-pubertal testicular teratomas, in contrast, almost all occur as one component of a mixed histology GCT, exhibit substantial cytogenetic abnormalities, typically being hyperdiploid and almost always including 12p amplification (Ulbright 2005) . In addition, these elements are generally treated as malignant, although their malignancy may be due to associated immature GCT components such as EC, rather than the mature teratoma component . Of the malignant childhood GCTs, YSTs are the most common in children under the age of 5 years whereas germinomas are predominantly diagnosed in the ovaries or in extragonadal sites of children over 5 years of age (Horton et al. 2007 , Murray & Nicholson 2010 .
Gain of chromosome 12p is a consistent feature of adult GCTs but is found at a lower incidence in childhood malignant tumours, which instead display unique cytogenetic abnormalities (loss on 1p, 4q and 6q in YSTs) (Palmer et al. 2007 , Frazier et al. 2012 . Gene expression analysis has suggested that childhood GCTs may have different expression profiles compared to their adult counterparts; the separation was especially striking between adult and paediatric YSTs (Palmer et al. 2008) . However, this difference was identified by comparing data from different published studies and so would be subject to the potential for batch effect variation (nonbiological experimental variation to which array-based experiments are very vulnerable (Johnson et al. 2007) ). A direct comparison of paediatric and adult samples in the same study is needed to determine how reliable these apparent differences might be. In addition, all childhood YSTs shared similar cytogenetic abnormalities and expression profiles regardless of age (Palmer et al. 2007 , Frazier et al. 2012 . This is in contrast to the classical separation of infantile YSTs from other malignant GCTs occurring in older children and adults, based on epidemiological, clinical and genetic features (Veltman et al. 2003 , Oosterhuis & Looijenga 2005 . Differences in the genetics, clinical aspects and expression profiles of adult and paediatric GCTs suggest that the mechanisms underlying their formation may be different (Veltman et al. 2003 , Palmer et al. 2007 .
The most widely accepted model for the origins of GCTs is that they all arise from totipotent PGCs, the precursors of normal germ cells. Extragonadal tumours are generally believed to arise when PGCs undergo aberrant migration along the midline of the developing embryo (Looijenga 2009 , Murray & Nicholson 2010 . Evidence that all adult GCTs share a common cellular origin includes the presence of similar cytogenetic abnormalities and an erasure of imprinting patterns in most GCTs (Kawakami et al. 2006 , Looijenga et al. 2007 . Interestingly, Schneider et al. (2001) suggested that childhood GCTs arise from more immature PGCs as they display only a partial erasure of imprinting patterns (Schneider et al. 2001) . A shared lineage relationship between subtypes of GCTs may explain the development of mixed tumours and the occasions in which a GCT that recurs after treatment is a different subtype to the primary lesion (reviewed in Tan & Scotting (2013) ). It is believed that in adults, both seminomatous and non-seminomatous GCTs can develop from precursor lesions termed intratubular germ cell neoplasia unclassified (IGCNU) (also called carcinoma in situ; CIS), although the lineage relationship is still debated ( Fig. 1 ; Skakkebaek et al. 1987 , Looijenga et al. 2007 , Rajpert-De Meyts & Skakkebaek 2011 .
Conventional treatment for malignant GCTs includes chemotherapy (cisplatin and other platinum-based drugs) and radiotherapy (seminomas only). Most GCTs have a remarkable sensitivity to cisplatin, allowing malignant GCTs to be highly curable (Oosterhuis & Looijenga 2005) . Relapse is observed for 10-50% of non-seminoma patients, although the use of alternative therapies allows survival in all but in a minority of cases. In children, prognosis depends on location and stage with an overall 5-year survival rate of 90% (Murray & Nicholson 2010) . Mediastinal YSTs are an exception, exhibiting the poorest prognosis in children and adults (Oosterhuis & Looijenga 2005 , Horton et al. 2007 . Despite the high cure rate for malignant GCTs, the intensive chemotherapy or combined chemo-radiotherapy is associated with long-term morbidity (van den Belt-Dusebout et al. 2007 ). This poses an even greater problem for paediatric patients in whom treatment can interfere with normal hormonal development and increase by approximately twofold the risk of cardiovascular disease and secondary malignancies (Murray & Nicholson 2010) . For this reason, better understanding of GCT biology, including the relationship between subtypes, the mechanistic basis for cisplatin resistance and the underlying differences between adult and childhood tumours, could allow the identification of novel biological targets for treatment.
In recent years, DNA methylation has become an increasing focus of study in GCTs. Aberrant epigenetic changes are widely believed to participate in cancer development (Cheung et al. 2009 ). In GCTs, DNA methylation is especially interesting as the methylation status of the genome is in flux during the normal development of germ cells. Aberrant development of germ cell precursors could potentially be caused by errors made during these dynamic changes in DNA methylation (Lind et al. 2007 , Beyrouthy et al. 2009 . A model where abnormal DNA methylation plays a particular role in GCT aetiology could explain the early occurrence and particular features of paediatric tumours. Indeed, cytogenetic or genetic aberrations are generally not detected in infantile teratomas, implying that the tumorigenic process includes mechanisms distinct from carcinogen-driven mutagenesis (Mostert et al. 2000) . Furthermore, DNA damage accumulation seems unlikely to explain the rapid development of paediatric tumours in a very short time span (including some that are diagnosed before birth) (Veltman et al. 2003) . Investigation of DNA methylation could therefore benefit our understanding of the unique and unexplained mechanisms underlying GCT biology.
DNA methylation in cancer
DNA methylation in vertebrates is an epigenetic modification that occurs almost exclusively on cytosines within a CpG dinucleotide. These sites tend to be clustered in 'CpG islands', which are found in the 5 0 -regions of 60-70% of human gene promoters. Unlike other CpG sites in the genome, those within an island are generally unmethylated in somatic cells and their methylation is involved in regulating gene expression in both normal development and carcinogenesis. Methylation of gene promoter regions is normally associated with transcriptional silencing, largely due to resulting modifications of chromatin structure (Esteller 2007 , Portela & Esteller 2010 . DNA methylation is carried out by the DNA methyltransferase (DNMT) family of enzymes, the catalytically active members of which are DNMT1, DNMT3A and DNMT3B. DNMT1 is involved in methylation maintenance, copying the methylation pattern onto the new DNA strand following DNA replication, whereas DNMT3A and DNMT3B are primarily responsible for establishing de novo methylation (Portela & Esteller 2010) .
Aberrant methylation has been reported in almost all cancer types and is considered a hallmark of cancer cells. At a genome-wide level, cancer cells display significant hypomethylation compared with normal cells. This is attributed to a loss of methylation in intergenic regions containing repetitive elements and is associated with chromosomal instability and activation of endogenous mobile DNA elements (Esteller 2007 , Portela & Esteller 2010 . On the other hand, hypermethylation of gene promoter regions is also seen in almost all cancer types with many reports of tumour suppressor genes being silenced (Cheung et al. 2009 , Dawson & Kouzarides 2012 . Silencing of some genes, such as RASSF1A, CDKN2A/p16 and MGMT, by promoter hypermethylation is especially common and is seen across many cancer types whereas methylation of other genes is much more cancer type specific (Esteller 2007 , Cheung et al. 2009 ).
In certain human neoplasms, elevated frequencies of gene promoter methylation are seen only in a subpopulation of those tumours. These are said to display a 'methylator phenotype' and can be associated with a specific genetic or clinical feature (Table 1 ). The first description of a methylator phenotype was in a subset of colon cancers said to have a CpG island methylator phenotype (CIMP; Toyota et al. 1999) . Subsequently, methylator phenotypes have been described in subpopulations of gliomas (Noushmehr et al. 2010) , breast cancers (Roll et al. 2008 , Bediaga et al. 2010 , Holm et al. 2010 , parathyroid tumours (Starker et al. 2011) , neuroblastomas (Alaminos et al. 2004 , Abe et al. 2005 , and GCTs (see below) (Lind et al. 2007 , Jeyapalan et al. 2011 . In colon cancer, early reports associated CIMPC tumours with a variety of clinical and genetic features; however, other studies failed to distinguish a distinct methylator phenotype (Toyota et al. 1999 , Yamashita et al. 2003 , Issa 2004 ). The inconsistencies reported were attributed to the use of different sample types and the particular gene targeted for methylation analysis (Weisenberger et al. 2006) . Using microarray technology and advanced clustering algorithms, more recent studies confirmed the existence of the CIMPC cancer subgroup (Ang et al. 2010 , Hinoue et al. 2012 ; see Table 1 ). Intriguingly, a study of breast cancer cell lines, which analysed differential methylation of candidate genes chosen for their differential gene expression between cell lines, identified a subset of breast cancers displaying a methylator phenotype exclusively associated with the basal-like subtype (Roll et al. 2008) . However, two later microarray studies targeting 1505 gene-associated CpG sites identified the basal-like subtype as rarely exhibiting promoter hypermethylation compared with the HER2-enriched and luminal B subtypes (Bediaga et al. 2010 , Holm et al. 2010 . This highlights the fact that studies using different approaches and targeting methylation of different gene sets can generate apparently conflicting results.
The underlying cause of aberrant DNA methylation in most cancers is not known. Abnormal DNMT activity has been associated with methylator phenotypes such as those seen in colorectal and breast cancers as well as GCTs (see below) (Roll et al. 2008 , Cheung et al. 2009 , Karpinski et al. 2010 . The only DNMT gene in which mutations have been described in relation to cancer is DNMT3A. Recurrent heterozygous mutations of DNMT3A have been identified in w22% of acute myeloid leukaemia patients and were associated with a poorer prognosis (Ley et al. 2010) . Yan et al. used MeDIP-chip analysis to identify 3878 genomic regions that showed differential methylation that correlated with the presence of mutated DNMT3A. Notably, these changes were linked to the increased expression of several HOX genes (Yan et al. 2011 ).
An issue that emerges when studying DNA methylation is the extent to which differential promoter methylation actually affects gene expression. In particular, the absence of promoter methylation does not necessarily guarantee that a gene will be expressed. Many studies have failed to determine whether gene expression is affected by the observed hypermethylation, leaving these studies unable to draw reliable conclusions about the functional importance of the methylation event (see Tables 1 and 2 ).
Recent issues in DNA methylation
Recent analyses of the spatial distribution of differentially methylated CpG sites have brought into question the relevance of previously reported methylation studies (Portela & Esteller 2010 , van Vlodrop et al. 2011 . Unbiased global methylation analyses using immunocapturing techniques demonstrated that aberrantly methylated regions in colon cancer cells were not restricted to CpG islands (Weber et al. 2005) . Genes with weak CpG islands in their promoter regions were also suggested to be preferentially targeted by de novo methylation during development (Weber et al. 2007) . Furthermore, genes with atypical CpG islands were regularly silenced by DNA methylation in breast MCF-7 cells implying that some isolated CpG sites, outside of defined CpG islands, can have functional relevance (Rivenbark et al. 2006 , Roll et al. 2008 .
Using an unbiased array-based method to analyse regions of aberrant methylation between various tissues and primary colon cancer samples, Irizarry et al. (2009) reported that both tissue and cancer-specific differentially methylated regions (T-DMR and C-DMRs respectively) are predominantly located to regions 2 kb on either side of CpG islands, termed CpG shores (Irizarry et al. 2009 ). Additionally, T-DMR and C-DMRs located in CpG shores were preferentially associated with gene expression changes (Ji et al. 2010 , Hansen et al. 2011 , Ogoshi et al. 2011 . It is worth noting that C-DMRs displaying hypermethylation in cancer tend to associate with regions close to CpG islands (54% are situated within 500 bp of a CpG island) whereas those showing hypomethylation rarely associate closely with CpG R52 M Cusack and P Scotting islands (Irizarry et al. 2009 ). Evidence that epigenetic silencing can occur over long distances (Frigola et al. 2006 , Tiwari et al. 2008 and that gene silencing can depend on the methylation of specific sites within CpG islands (Zinn et al. 2007 , Sohn et al. 2010 indicates that analysis of only a few CpG sites in a gene promoter region is likely to be insufficient to accurately reflect the methylation status of that gene (van Vlodrop et al. 2011) .
To avoid misinterpretation of methylation data and discrepancies such as those observed between breast cancer studies (Roll et al. 2008 , Bediaga et al. 2010 , Holm et al. 2010 , new methods are being used to facilitate identification of global methylation patterns in a CpG density-independent manner (Lister et al. 2009 , Bibikova et al. 2011 , Ogoshi et al. 2011 . In particular, genome-wide bisulphite sequencing (Lister et al. 2009) (Bibikova et al. 2011) can now be used to comprehensively describe entire methylomes. Such data will hopefully allow us to fully describe the association between methylation, gene expression and clinical features (Cheung et al. 2009 , Esteller 2011 , van Vlodrop et al. 2011 .
DNA methylation in GCTs
The analysis of methylation in GCTs has demonstrated that non-seminomatous tumours display an unusually strong and consistent methylator phenotype while seminomatous tumours exhibit an apparent lack of hypermethylation. This conclusion is based on studies using both candidate gene approaches (Koul et al. 2002 , Smith-Sorensen et al. 2002 , Honorio et al. 2003 , Kempkensteffen et al. 2006 , Lind et al. 2006 , Brait et al. 2012 ) and genome-wide approaches (Smiraglia et al. 2002 , Netto et al. 2008 , Wermann et al. 2010 , which have mainly focused on adult testicular GCTs (Table 2 ). Although some of these studies focused on a limited number of genes, microarray and genome-wide studies confirm that the methylation profile distinction between seminomas and non-seminomas is not restricted to just a few specific gene promoters (Lind et al. 2007 ).
Some studies propose that the methylation profile of both major GCT subtypes reflects their differentiation level and origin from PGCs (Smiraglia et al. 2002 , Lind et al. 2007 . During embryonic days 8.5-10.5, mouse PGCs undergo a genome-wide erasure of DNA methylation that affects different genes and genomic locations in two distinct waves (Arnaud 2010 , Hackett et al. 2012 . The striking hypomethylation observed in seminomatous tumours matches that displayed by foetal PGCs and also IGCNU precursor lesions including those associated with non-seminomatous elements in mixed tumours (Netto et al. 2008 , Wermann et al. 2010 . Smiraglia et al. (2002) suggested that CpG island methylation in non-seminomas could be associated with the increase in euchromatin DNA methylation occurring between days 16 and 17 in mouse male germ cells (Smiraglia et al. 2002) . Although the malignant non-seminomas exhibit increased hypermethylation (Netto et al. 2008 , Wermann et al. 2010 , they also exhibit hypomethylation of LINE1 repetitive elements (Jeyapalan et al. 2011 , Ushida et al. 2012 , which is reminiscent of other cancer cells and normal PGCs. The observation that different components of mixed tumours display distinct methylation profiles further supports the conclusion that aberrant methylation is a key factor in the development of GCT subtypes (Smith-Sorensen et al. 2002 , Honorio et al. 2003 , Netto et al. 2008 . Further analysis of the aberrant hypermethylation seen in non-seminomas will be necessary to determine whether 
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Except when stated otherwise, samples used were primary tumours and from testicular GCTs (TGCT). All studies that incorporated samples from other sites included tumours from both sexes. The studies reported in the last three rows focused on paediatric germ cell tumours. SE, seminomatous tumour; NS, non-seminomatous tumour; YST, yolk Sac tumour; CC, choriocarcinoma; TER, teratoma; EC, embryonal carcinoma; ICGNU, intratubular germ cell neoplasia unclassified; Mixed, tumours containing components from different histological subtypes; Normal, control/ normal tissue.
DNA methylation in germ cell tumour aetiology it reflects the unusual methylation events that are unique to developing PGCs. The differing methylation profiles of the various GCT subtypes appear to be independent of location, gender (Furukawa et al. 2009 , Wermann et al. 2010 , Jeyapalan et al. 2011 or genetic aberrations (Smiraglia et al. 2002 , Smith-Sorensen et al. 2002 , Lind et al. 2007 . With respect to age, differences between paediatric and adult GCTs have been suggested (Kato et al. 2003 , Furukawa et al. 2009 , Jeyapalan et al. 2011 Table 2 ), but this does not stand up to close scrutiny. These apparent differences when comparing non-seminomatous tumours between ages appear to reflect the differing predominant GCT subtypes between adults and children. For example, one of the most substantial studies in which a difference was suggested analysed 17 tumour suppressor genes concluding that several of the genes studied were more frequently hypermethylated in childhood YSTs than in an earlier study of adult testicular non-seminomas (Lind et al. 2006) . However, the adult group included a large proportion of EC samples (which showed almost no hypermethylation), the rest of the non-seminomas showing methylation levels similar to the paediatric study, which included very few EC samples (Furukawa et al. 2009 ). Analysis using the more comprehensive GoldenGate array confirmed the pronounced methylation phenotype of childhood YSTs: 10% of the genes analysed were hypermethylated in YSTs compared with seminomatous tumours, and in many cases, the methylation change was seen in almost all YST samples studied (Jeyapalan et al. 2011) . The methylation patterns reported here applied to children both above and below the age of 5 years. Like the consistent cytogenetic abnormalities described earlier, this contrasts the separation of infantile and YSTs from older children as proposed by others (Veltman et al. 2003 , Oosterhuis & Looijenga 2005 . Whether the differential gene expression profiles observed between paediatric and adult GCTs, particularly in YSTs, can be explained by DNA methylation changes remains to be determined (Palmer et al. 2008 , Jeyapalan et al. 2011 .
As in other cancers, studies reporting hypermethylation of putative tumour suppressors in GCTs have often failed to test directly whether those genes are actively silenced by their methylation or even to demonstrate whether differential methylation correlates with a difference in gene expression (Table 2) . Two studies directly analysed the expression of eight genes that might be influenced by differential DNA methylation but failed to identify a convincing relationship (Koul et al. 2002 , Smith-Sorensen et al. 2002 . Indeed, the four genes found to be inactive in the majority of tumours that displayed promoter hypermethylation (MGMT, MLH1, RARB and RASSF1A) were either silent in most tumours regardless of methylation state or failed to be reactivated by 5-aza-2 0 -deoxyticidine treatment (a nucleoside analogue that causes demethylation of DNA). A role for other gene regulatory factors was therefore suggested (Koul et al. 2002 , Smith-Sorensen et al. 2002 . Comparison of DNA methylation and gene expression data from matching samples allowed Jeyapalan et al. (2011) to identify eight genes for which decreased expression in paediatric YSTs compared with seminomatous tumours correlated with CpG hypermethylation. However, this represented only 1% of all genes analysed and only about 10% of the genes exhibiting differential methylation (Jeyapalan et al. 2011) . Using an alternative approach, Lind et al. (2006) identified 28 genes silenced in testicular GCTs but not in normal testes and reactivated by 5-aza-2 0 -deoxycytidine treatment in cell lines; however, when the methylation status of five of these genes was tested, none displayed promoter methylation in primary tumours. A potential explanation for the lack of correlation between methylation and gene silencing is the inappropriate analysis of very few CpG sites and only those within CpG islands. Two studies demonstrated that the PRSS21 gene was silenced by hypermethylation in GCTs, especially non-seminomas, after having identified which CpG sites were relevant to gene regulation (Manton et al. 2005 , Kempkensteffen et al. 2006 ). Hence, in most studies to date, there appears to be a poor correlation between methylation and gene silencing. If we are to fully understand the role and mechanism of gene silencing in cancer, it will, therefore, be crucial to establish the specific nature of the methylation events that do result in gene silencing.
Cause and consequence of DNA methylation in GCTs
Non-seminomatous tumours display particularly high frequencies of gene promoter hypermethylation compared with other cancers. This is particularly true for paediatric YSTs where almost all tumours showed elevated hypermethylation (Furukawa et al. 2009 , Jeyapalan et al. 2011 . Furthermore, apart from RASSF1A, APC, ESR1 and MGMT, the genes found to be hypermethylated in paediatric YSTs did not include those most commonly reported to be hypermethylated in other cancer types (Cheung et al. 2009 , Jeyapalan et al. 2011 . These differences suggest a unique mechanism underlying the aberrant methylation seen in GCTs, or at least paediatric YSTs.
The erasure and re-establishment of DNA methylation patterns as germ cell progenitors mature means that GCTs generally develop in a context in which unusual DNA methylation events are taking place (Hajkova 2011 , Hackett et al. 2012 . As malignant non-seminomas display aberrant methylation patterns, it has been suggested that disruption of the methylation events seen in PGCs is a key factor in their development (Lind et al. 2007 ). This disruption may refer to a failure to complete the dynamic erasure of DNA methylation patterns or failure in a later re-methylating event. Either way, one R56 M Cusack and P Scotting Reproduction (2013) 146 49-60 www.reproduction-online.org hypothesis is that these tumours derive from the aberrant activity of the methylation machinery at work in the developing PGC (Fig. 2) . Several members of the DNMT family have been implicated in the methylator phenotype of nonseminomatous GCTs. Increased expression of DNMT3B has been reported in EC cell lines compared with cell lines derived from other somatic cancers (Beyrouthy et al. 2009 ) and in paediatric YSTs compared with seminomatous tumours (Palmer et al. 2008 , Jeyapalan et al. 2011 . A number of genes preferentially methylated in YSTs were found to be targets for DNMT3B consistent with a role for this enzyme in establishing the methylator phenotype of GCTs (Jeyapalan et al. 2011) . The enzymatically inactive DNMT-like protein, DNMT3L, is believed to regulate target sites for de novo methylation (Wienholz et al. 2010) , particularly by recruiting DNMT3A and DNMT3B to heterochromatic regions associated with unmethylated lysine 4 on histone H3 tails (H3K4; Ooi et al. 2007 ). DNMT3L activity is potentially relevant to GCT development as it is specifically expressed in embryonic stem cells and in testicular germ cells during brief stages of development (Portela & Esteller 2010 , Wienholz et al. 2010 . It has also been reported to be necessary for the growth of EC cells (Minami et al. 2010) .
Technological advances now allow the analysis of individual CpG sites comprehensively covering the entire genome (Esteller 2011 , van Vlodrop et al. 2011 . We have performed a preliminary study using Infinium HumanMethylation450 BeadChips to assay methylation in CpG islands, shores, shelves and intergenic regions at a high resolution in teratoma, YST, seminoma and EC cell lines. This confirmed the hypermethylation profile of non-seminomas compared with seminomas but finds it to be restricted to CpG islands and CpG shores with islands showing the higher degree of differential methylation (D A Mohamed Noor, J Jeyapalan, M Cusack & P J Scotting, unpublished observations). Interestingly, this observation contrasts those of Irizarry et al. (2009) made in colon cancer, which may be representative of mechanistic differences underlying the aberrant methylation seen in these different tumour types.
Future directions
Although GCTs are a remarkably curable group of neoplasms, a better understanding of their biology is required to improve the treatment of those that are resistant to cisplatin (Wermann et al. 2010) . The discovery of novel biology-based therapeutic strategies is also particularly important to paediatric patients for which alternatives to chemotherapy are required (Murray & Nicholson 2010) . The discovery that a methylator phenotype is associated with malignant non-seminomatous tumours, which are more frequently resistant to therapy, but not seminomatous tumours or benign paediatric teratomas is a key step forward towards identifying factors that influence the clinical behaviour of GCTs (Lind et al. 2007 , Jeyapalan et al. 2011 , Poynter et al. 2011 . These are potential drug targets, especially if genome-wide promoter hypermethylation proves to be an initiating step in the development of more aggressive tumours. Technological advances in the analysis of DNA methylation will make it possible to accurately describe the relationship between differential methylation of specific CpG sites and gene expression (Portela & 2 -Hypermethylation is a later step in the development of non-seminomatous tumours.
Unique clinical and histological features
Non-seminomatous tumour Figure 2 Model representing the potential roles of hypermethylation in the development of nonseminomatous tumours. It remains to be clarified whether aberrant promoter methylation is (1) an initiating step in the development of non-seminomatous tumours or (2) a later aberrant alteration or a 'normal' feature of the cell types found in non-seminomatous tumours.
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